AG˹ٷ

STOCK TITAN

[Form 4] Axogen, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Axogen, Inc. (AXGN) � Form 4 insider filing

Director Amy McBride Wendell received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. The award is valued at $150,000 and represents the company’s standard director compensation. Each RSU converts to one common share upon vesting, which occurs in a single tranche on 06/19/2026, the one-year anniversary of the grant date. Following the transaction, Wendell’s directly held derivative position totals 14,150 RSUs; no open-market purchases or sales of common stock were reported. The filing does not indicate the adoption of a Rule 10b5-1 trading plan, and no other securities were acquired or disposed of.

Because the award is part of routine board compensation rather than an opportunistic purchase, the filing is unlikely to have a material impact on AXGN’s share price but does underscore continued alignment between the director and shareholder interests through equity-based pay.

Axogen, Inc. (AXGN) � Comunicazione interna Form 4

La direttrice Amy McBride Wendell ha ricevuto un assegno annuale di 14.150 unità azionarie vincolate (RSU) il 19/06/2025. Il premio ha un valore di 150.000 $ e rappresenta la consueta remunerazione per i membri del consiglio. Ogni RSU si converte in un’azione ordinaria al momento della maturazione, che avviene in un’unica tranche il 19/06/2026, anniversario di un anno dalla data di assegnazione. A seguito della transazione, la posizione derivata detenuta direttamente da Wendell ammonta a 14.150 RSU; non sono state segnalate compravendite di azioni ordinarie sul mercato aperto. Il documento non indica l’adozione di un piano di trading Rule 10b5-1 e non sono stati acquisiti o ceduti altri titoli.

Poiché il premio fa parte della normale retribuzione del consiglio e non di un acquisto opportunistico, la comunicazione difficilmente avrà un impatto significativo sul prezzo delle azioni AXGN, ma sottolinea l’allineamento continuo tra gli interessi della direttrice e degli azionisti tramite la remunerazione basata su azioni.

Axogen, Inc. (AXGN) � Presentación interna Formulario 4

La directora Amy McBride Wendell recibió una concesión anual de 14,150 unidades de acciones restringidas (RSU) el 19/06/2025. El premio tiene un valor de $150,000 y representa la compensación estándar para los miembros del consejo. Cada RSU se convierte en una acción común al momento de la consolidación, que ocurre en un solo tramo el 19/06/2026, un año después de la fecha de concesión. Tras la transacción, la posición derivada directa de Wendell suma 14,150 RSU; no se reportaron compras o ventas en el mercado abierto de acciones comunes. La presentación no indica la adopción de un plan de negociación Rule 10b5-1, ni se adquirieron o vendieron otros valores.

Dado que el premio es parte de la compensación habitual del consejo y no una compra oportunista, es poco probable que la presentación tenga un impacto material en el precio de las acciones de AXGN, pero sí destaca la alineación continua entre los intereses de la directora y los accionistas a través de la remuneración basada en acciones.

Axogen, Inc. (AXGN) � 내부� 신고� Form 4

이사 Amy McBride Wendell은 2025� 6� 19일에 연간 14,150개의 제한 주식 단위(RSU)� 부여받았습니다. � 보상은 150,000달러 상당으로 회사� 표준 이사 보상� 해당합니�. � RSU� 부여일로부� 1� 후인 2026� 6� 19� 단일 분할� 권리 확정 � 1� 보통주로 전환됩니�. 거래 � Wendell� 직접 보유� 파생 포지션은 14,150 RSU이며, 공개 시장에서� 보통� 매매� 보고되지 않았습니�. 신고서에� Rule 10b5-1 거래 계획 채택� 대� 언급� 없으�, 다른 증권� 취득 또는 처분� 없었습니�.

� 보상은 기회주의� 매수가 아닌 정기적인 이사� 보상� 일부이므�, 이번 신고가 AXGN 주가� 중요� 영향� 미칠 가능성은 낮지�, 주식 기반 보상� 통해 이사와 주주 � 이해관계가 지속적으로 일치하고 있음� 강조합니�.

Axogen, Inc. (AXGN) � Déclaration d’initié Formulaire 4

La directrice Amy McBride Wendell a reçu une attribution annuelle de 14 150 unités d’actions restreintes (RSU) le 19/06/2025. Cette récompense est évaluée à 150 000 $ et représente la rémunération standard des administrateurs. Chaque RSU se convertit en une action ordinaire lors de l’acquisition, qui a lieu en une seule tranche le 19/06/2026, soit un an après la date d’attribution. Suite à cette opération, la position dérivée détenue directement par Wendell s’élève à 14 150 RSU ; aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé. La déclaration n’indique pas l’adoption d’un plan de négociation Rule 10b5-1, et aucun autre titre n’a été acquis ou cédé.

Étant donné que cette attribution fait partie de la rémunération habituelle du conseil d’administration et non d’un achat opportuniste, cette déclaration est peu susceptible d’avoir un impact significatif sur le cours de l’action AXGN, mais elle souligne l’alignement continu des intérêts entre la directrice et les actionnaires via la rémunération en actions.

Axogen, Inc. (AXGN) � Insider-Meldung Form 4

Die Direktorin Amy McBride Wendell erhielt am 19.06.2025 eine jährliche Zuteilung von 14.150 Restricted Stock Units (RSUs). Die Auszeichnung hat einen Wert von 150.000 $ und stellt die übliche Vergütung für Direktoren dar. Jede RSU wird bei Vesting, das in einer einzigen Tranche am 19.06.2026, dem einjährigen Jahrestag des Zuteilungsdatums, erfolgt, in eine Stammaktie umgewandelt. Nach der Transaktion hält Wendell direkt 14.150 RSUs; keine Käufe oder Verkäufe von Stammaktien am offenen Markt wurden gemeldet. Die Meldung weist nicht auf die Einführung eines Rule 10b5-1 Handelsplans hin, und es wurden keine weiteren Wertpapiere erworben oder veräußert.

Da die Zuteilung Teil der routinemäßigen Vergütung des Vorstands ist und kein opportunistischer Kauf, wird die Meldung wahrscheinlich keinen wesentlichen Einfluss auf den Aktienkurs von AXGN haben, unterstreicht jedoch die fortgesetzte Ausrichtung der Interessen von Direktorin und Aktionären durch aktienbasierte Vergütung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine annual RSU grant; neutral market impact, modest alignment benefit.

The Form 4 shows a standard non-cash compensation event�14,150 RSUs valued at $150k issued to Director Amy Wendell. Vesting over one year is shorter than multi-year plans but consistent with many small-mid cap boards. No open-market buying means limited signaling value; however, the award marginally increases insider equity exposure, which governance best practice views favorably. With only 0.03�0.05% of shares outstanding (exact float not provided), dilution and market impact are negligible.

Axogen, Inc. (AXGN) � Comunicazione interna Form 4

La direttrice Amy McBride Wendell ha ricevuto un assegno annuale di 14.150 unità azionarie vincolate (RSU) il 19/06/2025. Il premio ha un valore di 150.000 $ e rappresenta la consueta remunerazione per i membri del consiglio. Ogni RSU si converte in un’azione ordinaria al momento della maturazione, che avviene in un’unica tranche il 19/06/2026, anniversario di un anno dalla data di assegnazione. A seguito della transazione, la posizione derivata detenuta direttamente da Wendell ammonta a 14.150 RSU; non sono state segnalate compravendite di azioni ordinarie sul mercato aperto. Il documento non indica l’adozione di un piano di trading Rule 10b5-1 e non sono stati acquisiti o ceduti altri titoli.

Poiché il premio fa parte della normale retribuzione del consiglio e non di un acquisto opportunistico, la comunicazione difficilmente avrà un impatto significativo sul prezzo delle azioni AXGN, ma sottolinea l’allineamento continuo tra gli interessi della direttrice e degli azionisti tramite la remunerazione basata su azioni.

Axogen, Inc. (AXGN) � Presentación interna Formulario 4

La directora Amy McBride Wendell recibió una concesión anual de 14,150 unidades de acciones restringidas (RSU) el 19/06/2025. El premio tiene un valor de $150,000 y representa la compensación estándar para los miembros del consejo. Cada RSU se convierte en una acción común al momento de la consolidación, que ocurre en un solo tramo el 19/06/2026, un año después de la fecha de concesión. Tras la transacción, la posición derivada directa de Wendell suma 14,150 RSU; no se reportaron compras o ventas en el mercado abierto de acciones comunes. La presentación no indica la adopción de un plan de negociación Rule 10b5-1, ni se adquirieron o vendieron otros valores.

Dado que el premio es parte de la compensación habitual del consejo y no una compra oportunista, es poco probable que la presentación tenga un impacto material en el precio de las acciones de AXGN, pero sí destaca la alineación continua entre los intereses de la directora y los accionistas a través de la remuneración basada en acciones.

Axogen, Inc. (AXGN) � 내부� 신고� Form 4

이사 Amy McBride Wendell은 2025� 6� 19일에 연간 14,150개의 제한 주식 단위(RSU)� 부여받았습니다. � 보상은 150,000달러 상당으로 회사� 표준 이사 보상� 해당합니�. � RSU� 부여일로부� 1� 후인 2026� 6� 19� 단일 분할� 권리 확정 � 1� 보통주로 전환됩니�. 거래 � Wendell� 직접 보유� 파생 포지션은 14,150 RSU이며, 공개 시장에서� 보통� 매매� 보고되지 않았습니�. 신고서에� Rule 10b5-1 거래 계획 채택� 대� 언급� 없으�, 다른 증권� 취득 또는 처분� 없었습니�.

� 보상은 기회주의� 매수가 아닌 정기적인 이사� 보상� 일부이므�, 이번 신고가 AXGN 주가� 중요� 영향� 미칠 가능성은 낮지�, 주식 기반 보상� 통해 이사와 주주 � 이해관계가 지속적으로 일치하고 있음� 강조합니�.

Axogen, Inc. (AXGN) � Déclaration d’initié Formulaire 4

La directrice Amy McBride Wendell a reçu une attribution annuelle de 14 150 unités d’actions restreintes (RSU) le 19/06/2025. Cette récompense est évaluée à 150 000 $ et représente la rémunération standard des administrateurs. Chaque RSU se convertit en une action ordinaire lors de l’acquisition, qui a lieu en une seule tranche le 19/06/2026, soit un an après la date d’attribution. Suite à cette opération, la position dérivée détenue directement par Wendell s’élève à 14 150 RSU ; aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé. La déclaration n’indique pas l’adoption d’un plan de négociation Rule 10b5-1, et aucun autre titre n’a été acquis ou cédé.

Étant donné que cette attribution fait partie de la rémunération habituelle du conseil d’administration et non d’un achat opportuniste, cette déclaration est peu susceptible d’avoir un impact significatif sur le cours de l’action AXGN, mais elle souligne l’alignement continu des intérêts entre la directrice et les actionnaires via la rémunération en actions.

Axogen, Inc. (AXGN) � Insider-Meldung Form 4

Die Direktorin Amy McBride Wendell erhielt am 19.06.2025 eine jährliche Zuteilung von 14.150 Restricted Stock Units (RSUs). Die Auszeichnung hat einen Wert von 150.000 $ und stellt die übliche Vergütung für Direktoren dar. Jede RSU wird bei Vesting, das in einer einzigen Tranche am 19.06.2026, dem einjährigen Jahrestag des Zuteilungsdatums, erfolgt, in eine Stammaktie umgewandelt. Nach der Transaktion hält Wendell direkt 14.150 RSUs; keine Käufe oder Verkäufe von Stammaktien am offenen Markt wurden gemeldet. Die Meldung weist nicht auf die Einführung eines Rule 10b5-1 Handelsplans hin, und es wurden keine weiteren Wertpapiere erworben oder veräußert.

Da die Zuteilung Teil der routinemäßigen Vergütung des Vorstands ist und kein opportunistischer Kauf, wird die Meldung wahrscheinlich keinen wesentlichen Einfluss auf den Aktienkurs von AXGN haben, unterstreicht jedoch die fortgesetzte Ausrichtung der Interessen von Direktorin und Aktionären durch aktienbasierte Vergütung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wendell Amy McBride

(Last) (First) (Middle)
C/O AXOGEN, INC. 13631 PROGRESS BLVD.
SUITE 400

(Street)
ALACHUA FL 32615

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 06/19/2025 A 14,150 (2) (2) Common Stock 14,150 $0 14,150 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
2. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.
Remarks:
/s/ Marc Began, as attorney-in-fact for Amy Wendell 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Axogen (AXGN) shares did Director Amy Wendell receive?

She received 14,150 restricted stock units, convertible to the same number of common shares upon vesting.

What is the dollar value of the RSU grant detailed in the Form 4?

The RSU award carries a $150,000 grant-date valuation.

When do the granted RSUs vest?

The units vest one year later on 06/19/2026.

Did the filing report any open-market purchases or sales by the director?

No; the Form 4 only discloses the RSU grant, with no common stock transactions.

Does the Form 4 mention a Rule 10b5-1 trading plan?

The form includes a checkbox reference, but no 10b5-1 plan was indicated as adopted for this transaction.
Axogen Inc

NASDAQ:AXGN

AXGN Rankings

AXGN Latest News

AXGN Latest SEC Filings

AXGN Stock Data

748.16M
43.86M
4.79%
87.52%
8.91%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
ALACHUA